Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Durability of antibody responses elicited by a single dose of Ad26.COV2.S and substantial increase following late boosting

Jerald Sadoff, Mathieu Le Gars, Vicky Cardenas, Georgi Shukarev, Nathalie Vaissiere, Dirk Heerwegh, Carla Truyers, Anne Marit de Groot, Gert Scheper, Jenny Hendriks, Javier Ruiz-Guiñazú, Frank Struyf, Johan Van Hoof, Macaya Douoguih, Hanneke Schuitemaker
doi: https://doi.org/10.1101/2021.08.25.21262569
Jerald Sadoff
1Janssen Vaccines and Prevention, Leiden, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jsadoff@its.jnj.com
Mathieu Le Gars
1Janssen Vaccines and Prevention, Leiden, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vicky Cardenas
2Janssen Research and Development, Spring House, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Georgi Shukarev
1Janssen Vaccines and Prevention, Leiden, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathalie Vaissiere
3Janssen Research and Development, Beerse, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dirk Heerwegh
3Janssen Research and Development, Beerse, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carla Truyers
3Janssen Research and Development, Beerse, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Marit de Groot
1Janssen Vaccines and Prevention, Leiden, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gert Scheper
1Janssen Vaccines and Prevention, Leiden, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jenny Hendriks
1Janssen Vaccines and Prevention, Leiden, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Javier Ruiz-Guiñazú
3Janssen Research and Development, Beerse, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank Struyf
3Janssen Research and Development, Beerse, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johan Van Hoof
1Janssen Vaccines and Prevention, Leiden, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Macaya Douoguih
1Janssen Vaccines and Prevention, Leiden, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hanneke Schuitemaker
1Janssen Vaccines and Prevention, Leiden, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background We evaluated the durability of SARS-CoV-2 antibody levels elicited by the single dose Janssen COVID-19 vaccine, Ad26.COV2.S, and the impact on antibody responses of boosting with Ad26.COV2.S after 6 months in clinical trial participants.

Methods Spike-binding antibody and SARS-CoV-2 neutralizing antibody levels elicited by a single-dose Ad26.COV2.S (5×1010 viral particles [vp]) primary regimen and booster doses (5×1010 vp and 1.25×1010 vp) were assessed by ELISA and wild-type VNA in sera from participants in a Phase 1/2a clinical trial (Cohort 1a, 18–55 years old, N=25; Cohort 2a, 18–55 years old boosted at 6 months, N=17; Cohort 3, ≥65 years old, N=22) and a Phase 2 clinical trial (18–55 and ≥65-year old participants boosted at 6 months, total N=73). Neutralizing antibody levels were determined approximately 8 months after the primary vaccination in participants aged 18–55 years and approximately 9 months in participants aged ≥65 years. Binding antibody levels were evaluated 6 months after primary vaccination and 7- and 28-days after booster doses in both age groups.

Results A single dose of Ad26.COV2.S elicited neutralizing antibodies that remained largely stable for approximately 8–9 months and binding antibodies that remained stable for at least 6 months irrespective of age group. A 5×1010 vp booster dose at 6 months post prime vaccination in 18–55-year-old adults elicited a steep and robust 9-fold increase at Day 7 post boost compared to Day 29 levels following the initial immunization. A lower booster dose of 1.25×1010 vp at 6 months in adults 18–55 and ≥65 years of age also elicited a rapid and high increase of 6–7.7 fold at Day 28 post boost compared to Day 29 levels following the initial immunization, with similar magnitude of post-boost responses in both age groups.

Conclusions A single dose of Ad26.COV2.S, which demonstrated protection in a Phase 3 efficacy trial, elicited durable neutralizing and binding antibodies for at least 8 and 6 months, respectively, in adults >18 years of age at levels similar to Day 29 responses. A 5×1010 vp or 1.25×1010 vp booster dose at 6 months elicited rapid and robust increases in spike binding antibody levels. The anamnestic responses after booster immunization imply robust immune memory elicited by single-dose Ad26.COV2.S.

Competing Interest Statement

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: all authors are employees of Janssen Pharmaceuticals, a Johnson & Johnson company.

Clinical Trial

NCT04436276; NCT04535453

Clinical Protocols

https://clinicaltrials.gov/ct2/show/NCT04436276

https://clinicaltrials.gov/ct2/show/NCT04535453

Funding Statement

Supported by Janssen Vaccines & Prevention B.V. in collaboration with the Biomedical Advanced Research and Development Authority, the National Institutes of Health, the Department of Defense, and the COVID-19 Prevention Network. This project has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract No. HHSO100201700018C.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All relevant ethical guidelines have been followed, all necessary IRB and/or ethics committee approvals have been obtained, all necessary patient/participant consent has been obtained and the appropriate institutional forms archived. The COV1001 study was reviewed and approved by local ethics committees (Comite d'Ethique Hospitalo-Facultaire Sain-Luc, Universite Catholique de Louvain on July 16, 2020) and institutional review boards (IRB) (approval by Advarra IRB on June 29 and July 10, 2020, for New Orleans Center for Clinical Research and Optimal Research sites, respectively). The COV2001 study was reviewed and approved by local ethics committees (Ethik-Kommission der Arztekammer Hamburg on August 19, 2020; Landesamt fur Gesundheit und Soziales Berlin Geschaftsstelle der Ethik-Kommission des Landes Berlin on August 26, 2020; Ethikkommission an der Medizinischen Fakultat der Universitat Rostock on September 01, 2020; and Raad van Bestuur UMC Utrecht on August 27, 2020) and regional ethics committees (Ethikkommission an der Medizinischen Fakultat der Universitat Rostock on September 01, 2020 and September 03, 2020; Comite Etico de Investigacion Clinica-Regional de la Comunidad de Madrid on August 28, 2020; and Central Committee on Research Involving Human Subjects (CCMO) on August 26, 2020. All participants provided written informed consent before enrollment. The trials adhere to the principles of the Declaration of Helsinki and to the Good Clinical Practice guidelines of the International Council for Harmonisation.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at https://www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at http://yoda.yale.edu.

https://www.janssen.com/clinical-trials/transparency

http://yoda.yale.edu

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted August 26, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Durability of antibody responses elicited by a single dose of Ad26.COV2.S and substantial increase following late boosting
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Durability of antibody responses elicited by a single dose of Ad26.COV2.S and substantial increase following late boosting
Jerald Sadoff, Mathieu Le Gars, Vicky Cardenas, Georgi Shukarev, Nathalie Vaissiere, Dirk Heerwegh, Carla Truyers, Anne Marit de Groot, Gert Scheper, Jenny Hendriks, Javier Ruiz-Guiñazú, Frank Struyf, Johan Van Hoof, Macaya Douoguih, Hanneke Schuitemaker
medRxiv 2021.08.25.21262569; doi: https://doi.org/10.1101/2021.08.25.21262569
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Durability of antibody responses elicited by a single dose of Ad26.COV2.S and substantial increase following late boosting
Jerald Sadoff, Mathieu Le Gars, Vicky Cardenas, Georgi Shukarev, Nathalie Vaissiere, Dirk Heerwegh, Carla Truyers, Anne Marit de Groot, Gert Scheper, Jenny Hendriks, Javier Ruiz-Guiñazú, Frank Struyf, Johan Van Hoof, Macaya Douoguih, Hanneke Schuitemaker
medRxiv 2021.08.25.21262569; doi: https://doi.org/10.1101/2021.08.25.21262569

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (228)
  • Allergy and Immunology (504)
  • Anesthesia (110)
  • Cardiovascular Medicine (1240)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (531)
  • Epidemiology (10023)
  • Forensic Medicine (5)
  • Gastroenterology (499)
  • Genetic and Genomic Medicine (2453)
  • Geriatric Medicine (238)
  • Health Economics (479)
  • Health Informatics (1644)
  • Health Policy (753)
  • Health Systems and Quality Improvement (636)
  • Hematology (248)
  • HIV/AIDS (533)
  • Infectious Diseases (except HIV/AIDS) (11864)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (252)
  • Medical Ethics (75)
  • Nephrology (268)
  • Neurology (2281)
  • Nursing (139)
  • Nutrition (352)
  • Obstetrics and Gynecology (454)
  • Occupational and Environmental Health (537)
  • Oncology (1245)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (324)
  • Pediatrics (730)
  • Pharmacology and Therapeutics (313)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2281)
  • Public and Global Health (4834)
  • Radiology and Imaging (837)
  • Rehabilitation Medicine and Physical Therapy (492)
  • Respiratory Medicine (651)
  • Rheumatology (285)
  • Sexual and Reproductive Health (238)
  • Sports Medicine (227)
  • Surgery (267)
  • Toxicology (44)
  • Transplantation (125)
  • Urology (99)